Association Between Visual Memory and

ADAD Alzheimer’s disease Amyloid Neuropsychological testing Preclinical Rey–Osterrieth Complex Figure Tau Visual memory

Journal

Journal of the International Neuropsychological Society : JINS
ISSN: 1469-7661
Titre abrégé: J Int Neuropsychol Soc
Pays: England
ID NLM: 9503760

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 9 8 2020
medline: 29 10 2021
entrez: 9 8 2020
Statut: ppublish

Résumé

Visual memory (ViM) declines early in Alzheimer's disease (AD). However, it is unclear whether ViM impairment is evident in the preclinical stage and relates to markers of AD pathology. We examined the relationship between ViM performance and in vivo markers of brain pathology in individuals with autosomal dominant AD (ADAD). Forty-five cognitively unimpaired individuals from a Colombian kindred with the Presenilin 1 (PSEN1) E280A ADAD mutation (19 carriers and 26 noncarriers) completed the Rey-Osterrieth Complex Figure immediate recall test, a measure of ViM. Cortical amyloid burden and regional tau deposition in the entorhinal cortex (EC) and inferior temporal cortex (IT) were measured using 11C-Pittsburgh compound B positron emission tomography (PET) and 11F-flortaucipir PET, respectively. Cognitively unimpaired carriers and noncarriers did not differ on ViM performance. Compared to noncarriers, carriers had higher levels of cortical amyloid and regional tau in both the EC and IT. In cognitively unimpaired carriers, greater cortical amyloid burden, higher levels of regional tau, and greater age were associated with worse ViM performance. Only a moderate correlation between regional tau and ViM performance remained after adjusting for verbal memory scores. None of these correlations were observed in noncarriers. Results suggest that AD pathology and greater age are associated with worse ViM performance in ADAD before the onset of clinical symptoms. Further investigation with larger samples and longitudinal follow-up is needed to examine the utility of ViM measures for identifying individuals at high risk of developing dementia later in life.

Identifiants

pubmed: 32762790
pii: S1355617720000673
doi: 10.1017/S1355617720000673
pmc: PMC8101259
mid: NIHMS1695063
doi:

Substances chimiques

Amyloid 0
Amyloid beta-Peptides 0
Presenilin-1 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-55

Subventions

Organisme : NIH HHS
ID : DP5 OD019833
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054671
Pays : United States

Références

JAMA Neurol. 2015 Mar;72(3):316-24
pubmed: 25580592
J Geriatr Psychiatry Neurol. 2008 Mar;21(1):26-33
pubmed: 18287167
Neurobiol Aging. 2013 Mar;34(3):822-31
pubmed: 22878163
Neurobiol Aging. 2014 Mar;35(3):576-84
pubmed: 24269021
Hum Brain Mapp. 2009 Dec;30(12):3981-92
pubmed: 19507155
Neuropsychologia. 2018 Jan 31;109:86-94
pubmed: 29237555
Alzheimers Dement (N Y). 2018 Mar 08;4:150-160
pubmed: 29955659
Hippocampus. 2011 Sep;21(9):929-34
pubmed: 21049490
Lancet Neurol. 2011 Mar;10(3):213-20
pubmed: 21296022
J Alzheimers Dis. 2015;43(2):677-86
pubmed: 25114076
Rev Neurol. 2007 Dec 1-15;45(11):655-60
pubmed: 18050096
Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677
pubmed: 29264389
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neurology. 2015 Sep 1;85(9):790-8
pubmed: 26245925
Ann Neurol. 2019 Feb;85(2):181-193
pubmed: 30549303
JAMA Neurol. 2018 May 1;75(5):548-556
pubmed: 29435558
JAMA Neurol. 2016 Jan;73(1):85-92
pubmed: 26595683
JAMA Psychiatry. 2018 Jan 1;75(1):84-95
pubmed: 29188296
Lancet Neurol. 2012 Dec;11(12):1057-65
pubmed: 23137949
Psychopharmacol Bull. 1988;24(4):653-9
pubmed: 3249767
Cereb Cortex. 2014 Aug;24(8):2210-8
pubmed: 23537530
Brain. 2019 Apr 1;142(4):1063-1076
pubmed: 30753379
J Clin Exp Neuropsychol. 1995 Aug;17(4):566-79
pubmed: 7593476
JAMA Neurol. 2016 Apr;73(4):431-8
pubmed: 26902171
Appl Neuropsychol Adult. 2021 Mar-Apr;28(2):230-244
pubmed: 31230490
J Clin Exp Neuropsychol. 2010 Feb;32(2):164-73
pubmed: 19459119
Neuropsychology. 2014 Jan;28(1):19-29
pubmed: 24219606
Brain. 2007 Nov;130(Pt 11):2837-44
pubmed: 17928318
N Engl J Med. 2012 Aug 30;367(9):795-804
pubmed: 22784036
Brain. 2017 Mar 1;140(3):748-763
pubmed: 28077397
Alzheimers Dement. 2017 Sep;13(9):1004-1012
pubmed: 28253478
J Neurosci. 2004 Apr 21;24(16):3917-25
pubmed: 15102907
Trends Cogn Sci. 2013 Jan;17(1):26-49
pubmed: 23265839
Neuron. 2006 Jul 20;51(2):251-61
pubmed: 16846859
Alzheimers Dement (Amst). 2017 Nov 06;10:66-74
pubmed: 29780858
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
JAMA Neurol. 2018 Jan 1;75(1):88-96
pubmed: 29114732
J Prev Alzheimers Dis. 2019;6(2):112-120
pubmed: 30756118
JAMA Neurol. 2018 Apr 1;75(4):488-494
pubmed: 29356823
Neurobiol Aging. 2018 Dec;72:177-185
pubmed: 30292840
Brain. 2014 Jan;137(Pt 1):221-31
pubmed: 24176981
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972

Auteurs

Yamile Bocanegra (Y)

Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Calle 62 No. 52-59, Medellín, Colombia.

Joshua T Fox-Fuller (JT)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.
Department of Psychological and Brain Sciences, Boston University, 900 Commonwealth Ave., 2nd Floor, Boston, MA02125, USA.

Ana Baena (A)

Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Calle 62 No. 52-59, Medellín, Colombia.

Edmarie Guzmán-Vélez (E)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.

Clara Vila-Castelar (C)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.

Jairo Martínez (J)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.

Heirangi Torrico-Teave (H)

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.

Francisco Lopera (F)

Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Calle 62 No. 52-59, Medellín, Colombia.

Yakeel T Quiroz (YT)

Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Calle 62 No. 52-59, Medellín, Colombia.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 100 1st Ave, Building 39, Suite 101, Charlestown, MA02129, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH